Arch-backed Neumora: using data tools for precision neuroscience

With more than $500 million from founding investor Arch, other VCs and partner Amgen, newly launched Neumora will aim to build on recent computational and data science advances to interrogate precision medicine targets in neuroscience and advance a pipeline that already includes eight programs, two of which have reached the clinic.

The broad idea is to take lessons from the evolution of precision oncology — specifically, thinking of cancer in terms of targets, mechanisms and genetics, rather than a set of diseases of particular organs — and apply them to neuropsychiatry and neurodegeneration, Arch Managing Director and Neumora founding Chairman and CEO Paul Berns told BioCentury...